Review of the present features and the infection control challenges of COVID-19 pandemic in dialysis facilities

Jia-Jung Lee1,2,3 | Shang-Jyh Hwang1,2,3 | Jee-Fu Huang2,4

1Division of Nephrology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
2Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
3Faculty of Renal Care, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
4Division of Hepatobiliary, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

Abstract
The COVID-19 has swept the world causing suffering, death, loss, and massive economy damage. The dialysis population is vulnerable and the dialysis facility is critical in maintaining operations and avoiding disease transmission. The present information regarding the clinical features of COVID-19 infection in the dialysis population was collected, and the useful measures of COVID-19 infection prevention and infection control in the dialysis facilities were summarized. Leadership, education, preparedness, management, and recovery phase were determined to be the critical procedures. It is hoped this updated interim review might provide information for medical professionals to take proactive action to best prepare and mitigate damage when facing the COVID-19 pandemic challenge.

KEYWORDS
COVID-19, hemodialysis, infection control

1 | INTRODUCTION

The world is now in the middle of the COVID-19 pandemic. Since a cluster of severe pneumonia cases was first noted in Wuhan, Hubei province, China in December 2019, this novel infection has spread rapidly and lethally and was declared pandemic by the World Health Organization on 11 March 2020. Principles of infection prevention and infection control are universal; however, critical measures and challenges vary at different medical settings and in different disease populations. Patients with regular dialysis treatment are usually older in age, have multiple comorbid diseases, and are relatively immune-compromised. Triweekly visits, lengthy duration of each treatment, proximity to medical staff, and shared space with a group of people together risk the dialysis facilities becoming a vector in COVID-19 transmission.1,2 Today, on 28 April 2020, there were 3,004,956 COVID-19-infected cases globally, causing 205,901 deaths, and affecting 184 countries. Taiwan has 429 COVID-19 confirmed cases with clinical presentation including 298 (69.6%) cases of mild disease, 95 (22.2%) cases of pneumonia, 35 (8.2%) cases of acute respiratory distress syndrome, and six deaths (1.4%).3 The first mortality case in Taiwan was a case of end-stage renal disease (ESRD) with peritoneal dialysis. The first two mortality cases in the United States were ESRD cases under regular hemodialysis (HD).4 A recent article and news also suggested increasing dialysis indication in severe COVID-19 patients.5–6 At this moment, physicians and scientists continue fighting at the front lines, swiftly collecting data, studying, and constantly learning about this novel contagious disease. Accordingly, this interim summary is not a comprehensive review but aims to update present clinical information and
infection control strategies currently focusing on COVID-19 control in dialysis facilities.

2 | THE PRESENT FEATURES OF COVID-19 INFECTION IN THE DIALYSIS POPULATION

At the beginning of the COVID-19 outbreak in China, one case series from a dialysis facility in Wuhan recorded the occurrence of 37 cases in 230 HD patients (16.1%) and four cases in 33 staff members (12.1%) during the 33-day period of time.7 Most of the cases had mild to no obvious symptoms (27/37, 72%), while bilateral multiple ground-glass opacity was prevalent in chest-computed tomography (CT) (23/37, 62%); however, one COVID-19-negative and six COVID-19-positive cases died during this period. The immune profile showed lower inflammatory cytokines of the HD COVID-19 case in comparison with non-HD cases.7

Another case series from a different hospital in Wuhan, China reported five COVID-19-positive cases in a cohort of 201 HD patients. The overall outcome of these five cases was favorable with no death or intubation while all cases had ground-glass opacity at the chest CT examination. Another remarkable point was that four of the five cases had symptoms of diarrhea.8 This symptom was in line with one reported case of ESRD with regular HD in the United States presenting with gastroenteritis symptoms and later developing severe pulmonary involvement.9

Till mid-April, most of the other published articles have not focused on dialysis populations, and only some related information can therefore be highlighted. In the first case series reported in the United States, in the presentation and outcome of 21 critically ill patients, the majority was linked to exposure at a skilled nursing facility. Fifteen of the 21 cases (71%) needed mechanical ventilation, and among these, 1150 (88%) needed invasive mechanical ventilation, five cases needed extracorporeal membrane oxygenation (ECMO) and among these, 11 cases (5%) needed invasive mechanical ventilation, three cases needed ECMO, and 15 deaths (1.4%) occurred.13 In another 191 adult inpatient with COVID-19 infection case series from Wuhan, China had a mean age of 56 years. Two of the 191 cases (1%) had CKD, and during the treatment course, 32 cases (17%) needed invasive mechanical ventilation, three cases needed ECMO (2%), and 10 cases (5%) needed renal replacement therapy. Acute cardiac injury occurred in 33 cases (17%), and AKI occurred in 28 cases (15%).14

From the above literature review, we could only tell that the appearance and level of COVID-19-infected HD patients is not uncommon. High mortality around 25% to 50% was observed in severe COVID-19 cases. However, it is still too early to obtain an accurate incidence or a detailed clinical course of COVID-19-infected HD patients. More complete and comprehensive studies focusing on COVID-19-infected HD cases are required for better understanding and caring for this vulnerable population.

3 | THE PRINCIPLES AND THE CRITICAL MEASURES FOR COVID-19 INFECTION CONTROL IN DIALYSIS FACILITIES

In the era of this pandemic, all dialysis facilities should be well prepared for providing dialysis to COVID-19-positive patients and to keep other patients and staff members healthy. Measures for infection prevention and control are based on science with the highest standards of care. Most importantly, when coming to dialysis, patient safety and health should be assured for all outpatients.1,15–17 Here, we summarize measures of COVID-19 infection control in dialysis facilities from present guidelines of different professional bodies (Table 1).1,15–20

3.1 | Leadership

Leadership is critical. Singular effort is required in communication with local health authorities and health departments as is coordination between departments and multiple disciplines to form a reactive working procedure. Assurance, transparency, communication, support for patients, dialysis, and medical staff are the important components of successful leadership.17,20
3.2 | Education

Professor Ikizler has emphasized the importance of patient and health care worker education. As the knowledge and evidence about COVID-19 is rapidly evolving and updating, this education should be on an ongoing basis. Knowledge concerning the transmission routes and characteristics of this RNA virus could enhance the compliance of people in infection prevention measures. Handwashing, respiratory hygiene, coughing etiquette, and adequate usage of personal protective equipment (PPE) are the key components. Information about the regional epidemic status and the identified clinical presentation of COVID-19 might also increase alertness.

3.3 | Preparedness

Professor Ikizler has also highlighted the importance of preparedness for the surge of patients focusing on waiting areas with signs and hand sanitizers, appropriate spacing with at least 6 ft in between individuals, and a triage plan. In Taiwan, we follow the government’s policies and the guidelines of the Taiwan Centers for Disease Control and Prevention (CDC). The Taiwan Society of Nephrology (TSN) has issued the “guidance of COVID-19 infection prevention in dialysis facilities” and published an article adding import proactive measures, including detail of the screening and triage strategy, traffic control bundle and checkpoint hands hygiene, a preplan divided work group and fixed caring team, and a full-time facemask usage policy.

The traffic control bundle includes designating the patient zone, the intermediate zone, and the clean zone to control the patient flow and to prevent nosocomial transmission, while a planned divided working group and a fixed caring team decrease staff-patient exposure. This fixed, cohort-actualized caring mode could minimize the infection risk in situations of high community transmission. Taking proactive action to design the patient allocation, controlling the patient flow, establishing a fixed caring team, and expanding the inventory of PPE are crucial components of preparedness during this pandemic era.

3.4 | Management

3.4.1 | Screening and triage

Professor Ikizler has also suggested advising patients to call ahead and report any fever or respiratory symptoms. In general, early recognition of symptomatic patient signs including fever, cough, upper airway involvement, or conjunctivitis and avoiding entrance to the waiting and treatment area is suggested. In Taiwan, all clinics and hospitals perform at-the-gate body temperature measurement and infectious risk assessment recording any recent travel, occupation, contact, and clustering (TOCC) history. The TOCC at present concerns every traveler from abroad who must abide by home quarantine for 14 days, health-care workers and staff related to transportation or travel business, those ever attending large-scale public or private activities, and recent health problems simultaneously occurring in family members, friends, or coworkers, while also considering any alerting symptoms including fever, respiratory symptoms, newly noticed loss of taste and smell, and diarrhea. Any symptomatic patient will be triaged and examined for COVID-19 at a separate area.

### TABLE 1 | Important measures of COVID-19 infection control in dialysis facilities

| Leadership                        |
|-----------------------------------|
| Coordination                      |
| Communication                     |
| Assurance, transparency, and support |

| Education                          |
|------------------------------------|
| Transmitted route: handwashing, respiratory hygiene, and coughing etiquette |
| Regional epidemic status           |
| Clinical presentation              |
| Adequate usage of personal protective equipment |

| Preparedness                        |
|------------------------------------|
| Triaging strategy: waiting area with signs and hand sanitizers, appropriate space with at least 6 ft in between |
| Traffic control bundle and checkpoint hands hygiene: design the patient zone, intermediate zone, clean zone, and control the patients flow |
| Divided work group and fixed caring team |
| Full-time facemask usage: expand the inventory of PPE |

| Management                          |
|------------------------------------|
| Screening and triage: travel, occupation, contact, and cluster |
| Patient allocation and PPE         |
| No infection, no TOCC risk: regular dialysis at the clean zone; dialysis standard percussion, full-time mask for all |
| No infection, with TOCC risk: exposure history, infectious status to be determined: the intermediate zone; high level PPE |
| COVID-19 confirmed case: isolation in the patient zone; alternatively, cohorting care in a confined section; highest level PPE |
| Environment disinfect              |
| Good indoor air ventilation        |
| Surface cleaning and disinfection  |
| Terminal station disinfection      |

| Recovery phase                     |
|------------------------------------|
| Step-down plan: step-by-step       |
| New normal life: source control with masking, keep social distance, stringent environment disinfect, hands hygiene |

| Promising therapies                |
|------------------------------------|
| Herd immunity                      |

Abbreviations: PPE, personal protective equipment; TOCC, travel, occupation, contact, and clustering.
3.4.2  Patient allocation and PPE

We allocate patients according to their COVID-19 infection status and the risk status. 15–17,21

Symptom-free, TOCC free

Patients with no symptoms and no exposure history or cluster history receive regular dialysis at the clean zone. Caring medical staff comply with dialysis standard precautions, while the patient and health-care workers wear facemasks in the treatment area. 19 In the updated CDC guidelines, to address asymptomatic and presymptomatic transmission, implementation of source control for everyone entering the health facilities is suggested. 19

Symptom-free, with TOCC risk

Patients having history of exposure are closely monitored for their health condition for 14 days after exposure. They may dialyze in the transition zone and the caring team is equipped with higher-level PPE, including shields or goggles for eye protection, N95 masks, waterproof isolation gowns, hair caps, and gloves. 16,17,21

The confirmed case

Patients are allocated to the patient zone, ideally, the negative pressure isolation room. If the medical capacity is exceeded, the COVID-19-infected patient with mild to moderate symptoms may dialyze in the outpatient area. Stringent compliance to the designated area, time, patient flow, checkpoint hygiene, and a fixed caring staff or necessary cohort mode (more than one patient) should be carried out. The caring team is equipped with the highest level of PPE including barrel suits if available. 17,18,21

3.4.3  Environment disinfection

The air conditioner should be operated full-time to maintain good indoor ventilation, while stringent cleaning and disinfecting of surfaces of the environment and equipment are mandatory as is the terminal station. The cleaning worker should be equipped with adequate PPE. 17,23

3.5  Recovery phase

Before the herd immunity and promising therapies available in the longer future, we may plan for a step-down strategy step-by-step. Source control with adequate masking, keeping social distance, cleaning, and disinfecting surfaces of the regular environment, and hand hygiene could become a normal part of life.

4  THE CHALLENGES AND THE CHANCES

The early report from China showed that COVID-19 was not associated with AKI or had relatively low incidence around 3% to 9% of AKI. 24,25 Updated and accumulated data have now shown the incidence of AKI is higher, up to 15% of the severe COVID-19 cases and is associated with high mortality. 26 The increased medical need for renal replacement therapy, hypercoagulation status, easy clotted filters, and the mandatory infection control setting are challenges for the medical system. 4,6 Furthermore, 34% to 65% of COVID-19-infected cases show occurring albuminuria and proteinuria. 15

Whether the renal injury and the hypercoagulation status are related to the cytokine storm or a direct cytopathic effect will need further investigation. 4,27–29

On the bright side, the intervention study of 53 severe COVID-19 hospitalized cases treated with compassionate use of remdesivir showed promising results. 30 The baseline oxygen saturation was 94% or less, 30 (57%) cases were under mechanical ventilation, and four (8%) cases needed ECMO. In a median follow-up of 18 days, 36 of 53 patients (68%) showed clinical improvement in the oxygen support class; 17 of the 30 (57%) intubated cases were weaned from the ventilator; 25 (47%) cases were discharged from hospital; and seven patients (13%) expired. 30 In addition, remdesivir showed efficacy against severe acute respiratory syndrome (SARS)-CoV in a mouse model. Remdesivir also had prophylactic and therapeutic effects in a nonhuman primate model of Middle East respiratory syndrome (MERS)-CoV infection. 31,32 Sulobutylether β-cyclodextrin sodium, an inactive ingredient of remdesivir, is renally cleared. 23 The inclusion criteria of the present remdesivir study required a creatinine clearance above 30 mL per minute, while the mean creatinine in the study was 0.89 mg/dL. 30 Ergo, the renal disease population will need further evidence and clinical trials in treating COVID-19-infected cases.

5  CONCLUSIONS

Today on 28 April 2020, 184 countries have been infected by COVID-19 and many countries and areas are in lockdown or in a shelter-in-place situation. Taiwan is doing well so far through attribution to effective and transparent leadership, proactive border control, and timely case identification and setting strategies and risk level of quarantine. 34 Updated information is important at this critical time for the world to battle the infection. Before more solid evidence and validation is available, this study is an interim brief based on the current accumulated information.

COVID-19 infecting dialysis patients are not uncommon and might be associated with poor prognosis. The dialysis facilities as an interface of hospital and community could be a center of vortex in infection transmission. Nephrologists should take proactive actions and work hard for COVID-19 infection prevention and infection control through the prevention, containment, mitigation, and recovery stages (Table 1).

ACKNOWLEDGMENTS

The authors thank the teamwork of the contingency team and the dialysis committee of the Taiwan Society of Nephrology.
CONFLICT OF INTEREST
The authors declare no potential conflict of interest.

ORCID
Jia-Jung Lee https://orcid.org/0000-0002-7951-9571
Shang-Jyh Hwang https://orcid.org/0000-0002-9404-3305
Jee-Fu Huang https://orcid.org/0000-0002-2752-7051

REFERENCES
1. Ikizler TA. COVID-19 and dialysis units: What do we know now and what should we do? Am J Kidney Dis. 2020;50(2):628-636. https://doi.org/10.1053/j.ajkd.2020.03.008.
2. Watnick S, McNamara E. On the frontline of the COVID-19 outbreak: Keeping patients on long-term dialysis safe. Clin J Am Soc Nephrol. 2020;15(5):710-713. https://doi.org/10.2215/CJN.03540320.
3. Taiwan Centers for Disease Control and Prevention: Taiwan CECC report on April 25, 2020. Available from: https://www.cdc.gov.tw/.
4. Durvasula R, Wellington T, McNamara E, Watnick S. COVID-19 and kidney failure in the acute care setting: Our experience from Seattle. Am J Kidney Dis. 2020;75(3):306-311. https://doi.org/10.1053/j.ajkd.2020.04.001.
5. Wadman M, Couzin-Franke J, Kaiser J, Matacic C. How does coronavirus kill? Clinicians trace a ferocious rampage through the body, from brain to toes. Science. April 17, 2020. Available from: https://www.sciencemag.org/news/2020/04/how-does-coronavirus-kill-clinicians-trace-ferocious-rampage-through-body-brain-toes.
6. Fox M. New COVID-19 crisis hits ICUs as more patients need dialysis. CNN. April 17, 2020. Available from: https://edition.cnn.com/2020/04/17/health/coronavirus-kidney-dialysis-need/index.html.
7. Ma YQ, Diao B, Lv XF, Zhu JL, Liang W, Liu L, et al. 2019 Novel coronavirus disease in hemodialysis (HD) patients: Report from one HD center in Wuhan, China. medRxiv preprint. Available from: https://doi.org/10.1101/2020.02.24.20027201.
8. Wang R, Liao C, He H, Hu C, Wei Z, Hong Z, et al. COVID-19 in Hemodialysis patients: A report of 5 cases. Am J Kidney Dis. 2020. https://doi.org/10.1053/j.ajkd.2020.03.009.
9. Ferrey AJ, Choi G, Hanna RM, Chang Y, Tantisattamo E, Ivaturi K, et al. A case of novel coronavirus disease 19 in a chronic hemodialysis patient with gastroenteritis and developing severe pulmonary disease. Am J Nephrol. 2020;51(5):337-342. https://doi.org/10.1159/000507471.
10. Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington state. JAMA. 2020;323(16):1612-1614. https://doi.org/10.1001/jama.2020.4326.
11. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA. 2020;323(16):1574-1581. https://doi.org/10.1001/jama.2020.5394.
12. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nallai AK, et al. Covid-19 in critically ill patients in the Seattle region-case series. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2004500.
13. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720. https://doi.org/10.1056/NEJMoa2002302.
14. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395(10229):1054-1062. https://doi.org/10.1016/S0140-6736(20)30565-0.
15. Naicker S, Yang CW, Hwang SJ, Liu BC, Chen JH, Jha V. The novel coronavirus 2019 epidemic and kidneys. Kidney Int. 2020;97(5):824-828. https://doi.org/10.1016/j.kint.2020.03.001.
16. Basile C, Combe C, Pizzarello F, Covic A, Davenport A, Kanbay M, et al. Recommendations for the prevention, mitigation and containment of the emerging SARS-CoV-2 (COVID-19) pandemic in haemodialysis centres. Nephrol Dial Transplant. 2020;35(5):737-741. https://doi.org/10.1093/ndt/gfaa069.
17. Kliger AS, Silberzweig J. Mitigating risk of COVID-19 in dialysis facilities. Clin J Am Soc Nephrol. 2020;15(5):737-741. https://doi.org/10.2215/CJN.03340320.
18. Lee JJ, Lin CY, Chiu YW, Hwang SJ. Take proactive measures for the pandemic COVID-19 infection in the dialysis facilities. J Formos Med Assoc. 2020;119(6):646(20):30116-30119. https://doi.org/10.1016/j.jfma.2020.03.022.
19. Centers for disease control and prevention: Interim additional guidance for infection prevention and control recommendations for patients with suspected or confirmed COVID-19 in outpatient hemodialysis facilities. Available from: https://www.cdc.gov/coronavirus/2019-ncov/healthcare-facilities/dialysis.html.
20. American Society of Nephrology: Recommendations on the care of hospitalized patients with COVID-19 and kidney failure requiring renal replacement therapy. Available from: https://www.asn-online.org/covid-19/ASN.
21. Taiwan Society of Nephrology: Guidance of COVID-19 infection prevention in dialysis facilities. April 6, 2020. Available from: https://www.twnsorgtgw/fsnFile/news/G8D7DB9AD62961/20200406-%E9%80%8F%E6%9E%8E%90%E9%86%AE%E7%99%92%E9%99%A2%E6%99%8E%9B%80%E6%87%90%E6%AD%A6%E6%BC%87%E8%2B%E7%82%ECV0ID-19%E6%8B%AF%E6%9F%93%E9%99%A7%E7%BD%AE%E8%6F%8F%E7%AF%84%E5%85%AC%E5%91%A8%E7%89%88%E7%AC%AE%E8%88%B9%E8%99%88-TSnpdf [Article in Chinese].
22. Yen MY, Lin YE, Lee CH, Ho MS, Huang FY, Chang SC, et al. Taiwan's traffic control bundle and the elimination of nosocomial severe acute respiratory syndrome among healthcare workers. J Hosp Infect. 2011;77(4):332-337.
23. Taiwan centers for disease control and prevention: Guidelines for infection control in medical institutions responding to COVID-19 infection. April 16, 2020. Available from: https://www.twnsorgtgw/fsnFile/Get/AnxF-73PUp26n5Z0Eea1mg [Article in Chinese].
24. Wang L, Li X, Chen H, Yan S, Li D, Li Y, et al. Coronavirus disease 19 infection does not result in acute kidney injury: An analysis of 116 hospitalized patients from Wuhan, China. Am J Nephrol. 2020;51(5):343-348. https://doi.org/10.1159/000507471.
25. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. https://doi.org/10.1016/S0140-6736(20)30183-5.
26. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97(5):829-838. https://doi.org/10.1016/j.kint.2020.03.005.
27. Pan XY, Xu D, Zhang H, Zhou W, Wang LH, Cui XG. Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: A study based on single-cell transcriptome analysis. Intensive Care Med. 2020. https://doi.org/10.1007/s00134-020-06026-1.
28. Su H, Yang M, Wan C, Yi LX, Tang F, Zhu HY, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020. https://doi.org/10.1016/j.kint.2020.04.003.
29. Ronco C, Reis T. Kidney involvement in COVID-19 and rationale for extracorporeal therapies. Nat Rev Nephrol. 2020;16:308-310. https://doi.org/10.1038/s41581-020-0284-7.
30. Grein J, Ohmagari N, Shin D, Díaz G, Asperges E, Castagna A, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2007016.
31. de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci U S A. 2020;117(12):6771–6776. https://doi.org/10.1073/pnas.1922083117.

32. Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):222. https://doi.org/10.1038/s41467-019-13940-6.

33. Remdesivir safety profile – covid March 9, 2020. Available from: https://www.su.krakow.pl/images/aktualnosci/2020/marzec/Safety_profile_Remdesivir.pdf.

34. Wang CJ, Ng CY, Brook RH. Response to COVID-19 in Taiwan: Big data analytics, new technology, and proactive testing. JAMA. 2020;323(14):1341–1342. https://doi.org/10.1001/jama.2020.3151.

How to cite this article: Lee J-J, Hwang S-J, Huang J-F. Review of the present features and the infection control challenges of COVID-19 pandemic in dialysis facilities. Kaohsiung J Med Sci. 2020;36:393–398. https://doi.org/10.1002/kjm2.12239